Human Umbilical Cord MSCs in the Treatment of Cerebral Palsy

Cerebral palsy in children is a disease that develops into paralysis due to brain parenchyma damage caused by various reasons (such as infection, bleeding, trauma, etc.) in childhood, with non-progressive and central motor dysfunction. Disorders, dystonia, posture and reflex abnormalities. It can also be accompanied by epilepsy, mental retardation, language impairment, visual and hearing impairment, etc. It is a lifelong disabling disease that seriously endangers children's health.

According to statistics, the incidence rate of children with cerebral palsy in developed countries is 1.8‰~4.9‰, and the incidence rate in my country is 1.8‰~6‰. That is to say, there is one cerebral palsy patient in every 400 newborns in my country.

At present, although there are more than 300 kinds of treatments for cerebral palsy at home and abroad, the effects are not satisfactory. Therefore, more and more researchers are paying attention to the treatment of cerebral palsy with mesenchymal stem cells.

Learn about the possibility of mesenchymal stem cell therapy

Mesenchymal stem cells (MSCs) are a type of pluripotent stem cells belonging to the mesoderm, which have the characteristics of high self-renewal ability, multi-directional differentiation potential, and immune regulation ability. Experiments have shown that mesenchymal stem cells can secrete a variety of neurotrophic factors, promote the repair of damaged cells, and activate dormant or functionally inhibited nerve cells, thereby improving the body's nerve function, enhancing the connection between synapses, and establishing new nerve cells. loop. Under specific circumstances, human umbilical cord mesenchymal stem cells can be induced to differentiate into neural stem cells.

Relevant studies have also shown that mesenchymal stem cell therapy has a good effect on the recovery of motor function in children with cerebral palsy, and can significantly reduce muscle tension and improve exercise capacity in children.

Umbilical cord mesenchymal stem cells are safe and effective in the treatment of cerebral palsy

The results of the clinical research project led by Taihe Hospital Affiliated to Hubei University of Medicine were published in the international journal "Stem Cell Research & Therapy"

Forty eligible patients were randomly divided into hUC-MSC (human umbilical cord mesenchymal stem cells) treatment group and control group. In addition to rehabilitation therapy, the hUC-MSC group received 4 intravenous infusions of hUC-MSCs, while the control group received placebo. Safety assessments (by adverse events (AEs) ) and efficacy (by Activities of Daily Living (ADL) scale, Comprehensive Health Function Assessment (CFA) and Gross Motor Function Assessment (GMFM) scales were performed through 12-month follow-up ) ).

The results showed that: a total of 39 patients received treatment and completed the scheduled evaluation. There was no significant difference in adverse events (AEs) between the hUC-MSC treatment group and the control group. In addition, ADL, CFA, and GMFM scale scores were significantly improved in the hUC-MSC-treated group compared with the control group. It shows that hUC-MSC transplantation combined with rehabilitation is safe and effective in improving gross motor and health functions in children with cerebral palsy. The umbilical cord mesenchymal stem cells in the hUC-MSC treatment group of this project are prepared and provided by Beike Bio, and a quality inspection report is issued for each batch of cell products in accordance with the standards of the International Cell Therapy Association before clinical use

The "Clinical Study on the Safety and Effectiveness of Human Umbilical Cord-derived Mesenchymal Stem Cells Combined with Modern Rehabilitation in the Treatment of Children with Cerebral Palsy" was jointly carried out by Shiyan Taihe Hospital Children's Medical Center and Shenzhen Beike Biotechnology Co., Ltd. The clinical medical projects registered by the National Health Commission and the State Drug Administration are currently recruiting patients.